RecruitingNCT05013632

COVID-19 International Drug Pregnancy Registry

COVID-19 International Drug Pregnancy Registry (COVID-PR)

Sponsor

Pregistry

Enrollment

2,000 participants

Start Date

Dec 1, 2021

Study Type

OBSERVATIONAL

Conditions

COVID19

Summary

The objective of the COVID-19 International Drug Pregnancy Registry (COVID-PR) is to evaluate obstetric, neonatal, and infant outcomes among women treated with monoclonal antibodies or antiviral drugs indicated for mild, moderate, or severe COVID-19 from the first day of the last menstrual period (LMP) to end of pregnancy. For monoclonal antibodies, the exposure period also includes 90 days prior to the first day of the LMP.

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 50 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Antiviral Agents and a drug called Monoclonal antibody for people with covid19. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 50 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.